| |
Learn about using biospecimen data to help ensure relevancy, quality and therefore reproducibility and accuracy of your research, as well as case studies on the impacts of failing to do so: Read More >>
|
|
Today’s Big NewsDec 6, 2024 |
| By Nick Paul Taylor Duality Biologics has shared the first data from a phase 1/2a antibody-drug conjugate trial, giving an early look at how the BioNTech-partnered asset is shaping up against rival molecules in development at companies including Merck & Co. |
|
|
|
By Nick Paul Taylor AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan at the second attempt. The partners showed off subgroup overall survival data that exceeded the result seen in the broader population, providing evidence to support the pivot. |
By Ayla Ellison,James Waldron This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay? |
By Gabrielle Masson At six months, Protara Therapeutics’ investigational cell therapy elicited a complete response rate of 72% among 18 patients with bladder cancer, data that sent the biotech’s shares surging. |
By James Waldron Cyclacel Pharmaceuticals will begin to slash its operating costs as the cancer-focused biotech explores "strategic alternatives on an expedited basis." |
By Darren Incorvaia,Zoey Becker President-elect Donald Trump has chosen Stanford University’s Jay Bhattacharya, M.D., Ph.D., to serve as the director of the National Institutes of Health. Bhattacharya is a physician, professor and economic researcher known for co-authoring a controversial open letter in October 2020 that called for an end to pandemic lockdowns. |
By Conor Hale Working with the real-world cancer data company COTA Healthcare, the former Fierce 15 winner put up its PreciseBreast test against Exact Sciences’ Oncotype DX. |
By Kevin Dunleavy Eli Lilly said it will spend $3 billion to transform a newly acquired, 84,000-square-foot plant in Kenosha, Wisconsin, into a massive complex that will produce injectables, including the company’s top-selling diabetes and obesity drugs Mounjaro and Zepbound. |
By Heather Landi Nontraditional providers will account for about one-third of the primary care market in 2030, according to Bain & Company. Payer-owned primary care, population-focused models and advanced primary care providers are all poised for growth. |
By Angus Liu Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in Singapore. GSK inked an antibody-drug conjugate deal with DualityBio and, through a revised agreement with Zhifei, dialed down its expectations for Shingrix in China for the next few years. And more. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore the biotech IPO market rebound and ask: Is the momentum here to stay? |
|
|---|
|
|
| WhitepaperWe interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
